Rohan Singh

Rohan Singh

Auto-generated profile, based on publicly available information

Rohan Singh

Memorial Sloan Kettering Cancer Center, New York, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
JJJustin Jee
Justin Jee
ABA. Rose Brannon
A. Rose Brannon
RSRohan Singh
Rohan Singh
ADAndriy Derkach
Andriy Derkach
CFChristopher Fong
Christopher Fong
SMSimon Mantha
Simon Mantha
Cancer-associated venous thromboembolism (VTE) is a major source of oncologic cost, morbidity and mortality. Identifying high-risk patients for prophylactic anticoagulation is challenging and adds to clinician burden. Circulating tumor DNA (ctDNA) sequencing assays (‘liquid biopsies’) are widely implemented, but their utility for VTE prognostication is unknown. Here we analyzed three plasma sequencing cohorts: a pan-cancer discovery cohort of 4,141 patients with non-small cell lung cancer (NSCLC) or breast, pancreatic and other cancers; a prospective validation cohort consisting of 1,426 patients with the same cancer types; and an international generalizability cohort of 463 patients with advanced NSCLC. ctDNA detection was associated with VTE independent of clinical and radiographic features. A machine learning model trained on liquid biopsy data outperformed previous risk scores (discovery, validation and generalizability c-indices 0.74, 0.73 and 0.67, respectively, versus 0.57, 0.61 and 0.54 for the Khorana score). In real-world data, anticoagulation was associated with lower VTE rates if ctDNA was detected (n = 2,522, adjusted hazard ratio (HR) = 0.50, 95% confidence interval (CI): 0.30–0.81); ctDNA− patients (n = 1,619) did not benefit from anticoagulation (adjusted HR = 0.89, 95% CI: 0.40–2.0). These results provide preliminary evidence that liquid biopsies may improve VTE risk stratification in addition to clinical parameters. Interventional, randomized prospective studies are needed to confirm the clinical utility of liquid biopsies for guiding anticoagulation in patients with cancer.

16 May 2024 in Bleeding, Thrombosis and Vascular Biology
Verified
Journal Article
Open access
PDF file
RPRushad Patell
Rushad Patell
JZJeffrey I. Zwicker
Jeffrey I. Zwicker
RSRohan Singh
Rohan Singh
SMSimon Mantha
Simon Mantha
The goal of machine learning (ML) is to create informative signals and useful tasks by leveraging large datasets to derive computational algorithms. ML has the potential to revolutionize the healthcare industry by boosting productivity, enhancing safe and effective patient care, and lightening the load on clinicians. In addition to gaining mechanistic insights into cancer-associated thrombosis (CAT), ML can be used to improve patient outcomes, streamline healthcare delivery, and spur innovation. Our review paper delves into the present and potential applications of this cutting-edge technology, encompassing three areas: i) computer vision-assisted diagnosis of thromboembolism from radiology data; ii) case detection from electronic health records using natural language processing; iii) algorithms for CAT prediction and risk stratification. The availability of large, well-annotated, high-quality datasets, overfitting, limited generalizability, the risk of propagating inherent bias, and a lack of transparency among patients and clinicians are among the challenges that must be overcome in order to effectively develop ML in the health sector. To guarantee that this powerful instrument can be utilized to maximize innovation in CAT, clinicians can collaborate with stakeholders such as computer scientists, regulatory bodies, and patient groups.

15 September 2023
Verified
Book Chapter
Closed access
PDF file
SSSarthak Singh
Sarthak Singh
RSRohan Singh
Rohan Singh
AGArkaprovo Ghosal
Arkaprovo Ghosal
TMTanmaya Mahapatra
Tanmaya Mahapatra
Diabetes mellitus is one of the most common diseases, so an efficient method for predicting it can help with self-diagnosis. Machine learning (ML) can detect patterns from data to predict the disease. The conventional way to identify diabetes is a blood glucose test; therefore, most patients cannot get an immediate diagnosis. In this chapter, we discuss five well-known and state-of-the-art ML algorithms, including logistic regression, support vector machines, random forest, XGBoost, and neural networks to predict diabetes mellitus. We have used the dataset from the University of California, Irvine (UCI) ML repository collected by a direct survey of patients from Sylhet Diabetes Hospital. An optional library has been used for tuning hyperparameters for various algorithms. We have used the model averaging ensemble model by stacking random forest, XG-Boost, and neural network together and comparing performance using accuracy as a metric. The best accuracy was 98.08%, achieved by using a neural network with two hidden layers. We provide a comparative discussion of our approach and results with all the other existing methods in the literature. The results demonstrated in this chapter present a significant improvement in diabetes prediction using ML over the established state-of-the-art. <!----> <!----> <!----> <!---->